{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:51:50Z","timestamp":1792014710526,"version":"4.4.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Perinatology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clp.2019.02.002","type":"journal-article","created":{"date-parts":[[2019,3,30]],"date-time":"2019-03-30T08:29:00Z","timestamp":1553934540000},"page":"173-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Treatment and Prevention of Hypertensive Disorders During Pregnancy"],"prefix":"10.1016","volume":"46","author":[{"given":"Karla","family":"Leavitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Obi\u010dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Yankowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clp.2019.02.002_bib1","series-title":"Maternal-fetal medicine: principles and practice","author":"Creasy","year":"2004"},{"issue":"9516","key":"10.1016\/j.clp.2019.02.002_bib2","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(06)68397-9","article-title":"WHO analysis of causes of maternal death: a systematic review","volume":"367","author":"Khan","year":"2006","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clp.2019.02.002_bib3","first-page":"1122","article-title":"Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on hypertension in pregnancy","volume":"122","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.clp.2019.02.002_bib4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0002-9378(99)70239-5","article-title":"Preeclampsia: an excessive maternal inflammatory response to pregnancy","volume":"180","author":"Redman","year":"1999","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.clp.2019.02.002_bib5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0002-9378(98)70254-6","article-title":"Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis","volume":"179","author":"Sacks","year":"1998","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"10.1016\/j.clp.2019.02.002_bib6","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1172\/JCI119387","article-title":"Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion?","volume":"99","author":"Zhou","year":"1997","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.clp.2019.02.002_bib7","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/humrep\/deu017","article-title":"Increased angiogenic factor secretion by decidual natural killer cells from pregnancies with high uterine artery resistance alters trophoblast function","volume":"29","author":"Wallace","year":"2014","journal-title":"Hum Reprod"},{"issue":"2","key":"10.1016\/j.clp.2019.02.002_bib8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/0002-9378(90)91176-D","article-title":"Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986","volume":"163","author":"Saftlas","year":"1990","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.clp.2019.02.002_bib9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/oxfordjournals.epirev.a017954","article-title":"Epidemiology of pregnancy-induced hypertension","volume":"19","author":"Zhang","year":"1997","journal-title":"Epidemiol Rev"},{"issue":"2","key":"10.1016\/j.clp.2019.02.002_bib10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jama.1991.03470020063033","article-title":"A\u00a0multivariate analysis of risk factors for preeclampsia","volume":"266","author":"Eskenazi","year":"1991","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.clp.2019.02.002_bib11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.annepidem.2004.12.008","article-title":"The risk of preeclampsia rises with increasing prepregnancy body mass index","volume":"15","author":"Bodnar","year":"2005","journal-title":"Ann Epidemiol"},{"issue":"4","key":"10.1016\/j.clp.2019.02.002_bib12","first-page":"614","article-title":"Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience","volume":"80","author":"Branch","year":"1992","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.clp.2019.02.002_bib13","first-page":"131","article-title":"A\u00a0study of sixty pregnancies in patients with the antiphospholipid syndrome","volume":"14","author":"Lima","year":"1996","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.clp.2019.02.002_bib14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/AOG.0000000000002115","article-title":"National partnership for maternal safety: consensus bundle on severe hypertension during pregnancy and the postpartum period","volume":"130","author":"Bernstein","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.clp.2019.02.002_bib15","article-title":"Antihypertensive drug therapy for mild to moderate\u00a0hypertension during pregnancy","author":"Abalos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"3 Pt 2","key":"10.1016\/j.clp.2019.02.002_bib16","first-page":"Ii21","article-title":"Beta-adrenergic receptor blockers. Adverse effects and drug interactions","volume":"11","author":"Frishman","year":"1988","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.clp.2019.02.002_bib17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2125.1980.tb01784.x","article-title":"Effects of nifedipine on resistance vessels, arteries and veins in man","volume":"10","author":"Robinson","year":"1980","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.clp.2019.02.002_bib18","article-title":"Oral beta-blockers for mild to moderate hypertension during pregnancy","author":"Magee","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"6752","key":"10.1016\/j.clp.2019.02.002_bib19","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/bmj.301.6752.587","article-title":"Atenolol in essential hypertension during pregnancy","volume":"301","author":"Butters","year":"1990","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.clp.2019.02.002_bib20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0022-3476(95)70277-6","article-title":"Use of glucagon to treat neonatal low-output congestive heart failure after maternal labetalol therapy","volume":"127","author":"Stevens","year":"1995","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"10.1016\/j.clp.2019.02.002_bib21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1081\/PRG-120028291","article-title":"Do commonly used oral antihypertensives alter fetal or neonatal heart rate characteristics? A systematic review","volume":"23","author":"Waterman","year":"2004","journal-title":"Hypertens Pregnancy"},{"issue":"2","key":"10.1016\/j.clp.2019.02.002_bib22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/0002-9378(90)90386-L","article-title":"Labetalol pharmacokinetics in pregnancy-induced hypertension","volume":"162","author":"Rogers","year":"1990","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.clp.2019.02.002_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/00003088-198814040-00003","article-title":"Drugs in human milk. Clinical pharmacokinetic considerations","volume":"14","author":"Atkinson","year":"1988","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.clp.2019.02.002_bib24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0301-2115(00)00548-0","article-title":"Calcium channel blockers in the management of preterm labor and hypertension in pregnancy","volume":"97","author":"Papatsonis","year":"2001","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"12","key":"10.1016\/j.clp.2019.02.002_bib25","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1471-0528.1988.tb06818.x","article-title":"The effect of sublingual nifedipine on uteroplacental blood flow in hypertensive pregnancy","volume":"95","author":"Lindow","year":"1988","journal-title":"Br J Obstet Gynaecol"},{"issue":"3","key":"10.1016\/j.clp.2019.02.002_bib26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000298796","article-title":"Effects of nifedipine on umbilical artery velocity waveforms in healthy human fetuses","volume":"24","author":"Rizzo","year":"1987","journal-title":"Gynecol Obstet Invest"},{"issue":"5","key":"10.1016\/j.clp.2019.02.002_bib27","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/AOG.0b013e3182a9ea68","article-title":"Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy: a randomized controlled trial","volume":"122","author":"Shekhar","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"10","key":"10.1016\/j.clp.2019.02.002_bib28","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1471-0528.1993.tb15120.x","article-title":"Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33\u00a0weeks","volume":"100","author":"Impey","year":"1993","journal-title":"Br J Obstet Gynaecol"},{"issue":"4","key":"10.1016\/j.clp.2019.02.002_bib29","first-page":"192","article-title":"The effect of nifedipine on fetal umbilical artery Doppler waveforms in pregnancies complicated by hypertension","volume":"79","author":"Puzey","year":"1991","journal-title":"S\u00a0Afr Med J"},{"issue":"4","key":"10.1016\/j.clp.2019.02.002_bib30","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1067\/mob.2002.126294","article-title":"Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy","volume":"187","author":"Brown","year":"2002","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.clp.2019.02.002_bib31","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0002-9378(90)90867-7","article-title":"Magnesium plus nifedipine","volume":"162","author":"Ales","year":"1990","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.clp.2019.02.002_bib32","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1471-0528.1994.tb13126.x","article-title":"The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade","volume":"101","author":"Ben-Ami","year":"1994","journal-title":"Br J Obstet Gynaecol"},{"issue":"2","key":"10.1016\/j.clp.2019.02.002_bib33","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0002-9378(88)80072-3","article-title":"Magnesium plus nifedipine: potentiation of hypotensive effect in preeclampsia?","volume":"159","author":"Waisman","year":"1988","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.clp.2019.02.002_bib34","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0002-9378(96)70143-6","article-title":"Hemodynamic effects of oral nifedipine in preeclamptic hypertensive emergencies","volume":"175","author":"Scardo","year":"1996","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.clp.2019.02.002_bib35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ajog.2004.11.059","article-title":"Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia","volume":"193","author":"Magee","year":"2005","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.clp.2019.02.002_bib36","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1542\/peds.108.3.776","article-title":"Transfer of drugs and other chemicals into human milk","volume":"108","year":"2001","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.clp.2019.02.002_bib37","first-page":"1148","article-title":"Pheochromocytoma and pregnancy: the epitome of high risk","volume":"114","author":"Freier","year":"1993","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.clp.2019.02.002_bib38","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0002-9378(90)91297-P","article-title":"A\u00a0comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy","volume":"162","author":"Sibai","year":"1990","journal-title":"Am J Obstet Gynecol"},{"issue":"7566","key":"10.1016\/j.clp.2019.02.002_bib39","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0140-6736(68)90650-8","article-title":"A\u00a0controlled trial of hypotensive agents in hypertension in pregnancy","volume":"2","author":"Leather","year":"1968","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.clp.2019.02.002_bib40","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1751-7176.2009.00186.x","article-title":"Hypertension in the postpartum woman: clinical update for the hypertension specialist","volume":"11","author":"Ghuman","year":"2009","journal-title":"J\u00a0Clin Hypertens"},{"issue":"6","key":"10.1016\/j.clp.2019.02.002_bib41","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0016-5085(74)80013-2","article-title":"Acute submassive hepatic necrosis due to methyldopa. A case demonstrating possible initiation of chronic liver disease","volume":"66","author":"Schweitzer","year":"1974","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.clp.2019.02.002_bib42","first-page":"634","article-title":"Clonidine hydrochloride: a safe and effective antihypertensive agent in pregnancy","volume":"66","author":"Horvath","year":"1985","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.clp.2019.02.002_bib43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/10641950701204430","article-title":"Management of severe hypertension in the postpartum period with intravenous hydralazine or labetalol: a randomized clinical trial","volume":"26","author":"Vigil-De Gracia","year":"2007","journal-title":"Hypertens Pregnancy"},{"issue":"8","key":"10.1016\/j.clp.2019.02.002_bib44","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0195-668X(03)00098-8","article-title":"Expert consensus document on management of cardiovascular diseases during pregnancy","volume":"24","year":"2003","journal-title":"Eur Heart J"},{"issue":"7421","key":"10.1016\/j.clp.2019.02.002_bib45","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/bmj.327.7421.955","article-title":"Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis","volume":"327","author":"Magee","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.clp.2019.02.002_bib46","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/01.AOG.0000460762.59152.d7","article-title":"Committee Opinion No. 623: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period","volume":"125","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"6461","key":"10.1016\/j.clp.2019.02.002_bib47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/bmj.290.6461.17","article-title":"Overview of randomised trials of diuretics in pregnancy","volume":"290","author":"Collins","year":"1985","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.clp.2019.02.002_bib48","article-title":"Prevention and treatment of postpartum hypertension","author":"Magee","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.clp.2019.02.002_bib49","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/0002-9378(95)90549-9","article-title":"Spironolactone therapy during human pregnancy","volume":"172","author":"Groves","year":"1995","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.clp.2019.02.002_bib50","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00228-009-0620-0","article-title":"Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants","volume":"65","author":"Lennestal","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clp.2019.02.002_bib51","doi-asserted-by":"crossref","first-page":"658310","DOI":"10.1155\/2012\/658310","article-title":"The fetal safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers","volume":"2012","author":"Moretti","year":"2012","journal-title":"Obstet Gynecol Int"},{"issue":"8","key":"10.1016\/j.clp.2019.02.002_bib52","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/pds.796","article-title":"Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment","volume":"12","author":"Tabacova","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.clp.2019.02.002_bib53","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1479-828X.1998.tb03072.x","article-title":"Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy","volume":"38","author":"Burrows","year":"1998","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"3","key":"10.1016\/j.clp.2019.02.002_bib54","first-page":"429","article-title":"Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors","volume":"80","author":"Piper","year":"1992","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.clp.2019.02.002_bib55","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF00314815","article-title":"The excretion of enalapril and enalaprilat in human breast milk","volume":"38","author":"Redman","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.clp.2019.02.002_bib56","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1007\/s00125-010-2040-1","article-title":"Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo- controlled DIabetic REtinopathy Candesartan Trials","volume":"54","author":"Porta","year":"2011","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.clp.2019.02.002_bib57","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/bdra.20102","article-title":"Angiotensin II receptor antagonist treatment during pregnancy","volume":"73","author":"Alwan","year":"2005","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"3","key":"10.1016\/j.clp.2019.02.002_bib58","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1365-2125.2012.04388.x","article-title":"Angiotensin-II receptor 1 antagonist fetopathy: risk assessment, critical time period and vena cava thrombosis as a possible new feature","volume":"75","author":"Oppermann","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.clp.2019.02.002_bib59","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-0030-1269895","article-title":"Angiotensin II receptor blocker induced fetopathy: 7 cases","volume":"223","author":"Hunseler","year":"2011","journal-title":"Klin Padiatr"},{"issue":"3","key":"10.1016\/j.clp.2019.02.002_bib60","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.reprotox.2010.01.010","article-title":"Reversible fetal renal failure after maternal treatment with Candesartan: a case report","volume":"29","author":"Munk","year":"2010","journal-title":"Reprod Toxicol"},{"issue":"1","key":"10.1016\/j.clp.2019.02.002_bib61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1345\/aph.1E250","article-title":"Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth","volume":"39","author":"Bos-Thompson","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"8","key":"10.1016\/j.clp.2019.02.002_bib62","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/bdra.20047","article-title":"Fetal toxicity of valsartan and possible reversible adverse side effects","volume":"70","author":"Berkane","year":"2004","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"2","key":"10.1016\/j.clp.2019.02.002_bib63","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1161\/HYPERTENSIONAHA.112.196352","article-title":"Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review","volume":"60","author":"Bullo","year":"2012","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.clp.2019.02.002_bib64","doi-asserted-by":"crossref","first-page":"695","DOI":"10.7326\/M13-2844","article-title":"Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force","volume":"160","author":"Henderson","year":"2014","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.clp.2019.02.002_bib65","article-title":"Antiplatelet agents for preventing pre-eclampsia and its complications","author":"Duley","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.clp.2019.02.002_bib66","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2393-5-7","article-title":"Antiplatelet agents for prevention of pre-eclampsia and its consequences: a systematic review and individual patient data meta-analysis","volume":"5","author":"Askie","year":"2005","journal-title":"BMC Pregnancy Childbirth"},{"issue":"7","key":"10.1016\/j.clp.2019.02.002_bib67","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.clp.2019.02.002_bib68","doi-asserted-by":"crossref","first-page":"503.e1-12","DOI":"10.1016\/j.ajog.2011.02.020","article-title":"Supplementation with vitamins C and E during pregnancy for the prevention of preeclampsia and other adverse maternal and perinatal outcomes: a systematic review and metaanalysis","volume":"204","author":"Conde-Agudelo","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clp.2019.02.002_bib69","series-title":"WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia","year":"2011"}],"container-title":["Clinics in Perinatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095510819300090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095510819300090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:57:45Z","timestamp":1758815865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0095510819300090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0095510819300090"],"URL":"https:\/\/doi.org\/10.1016\/j.clp.2019.02.002","relation":{},"ISSN":["0095-5108"],"issn-type":[{"value":"0095-5108","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment and Prevention of Hypertensive Disorders During Pregnancy","name":"articletitle","label":"Article Title"},{"value":"Clinics in Perinatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clp.2019.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}